Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage. 

Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.

CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.

Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.